Public Companies Are Dizal (Jiangsu) Pharmaceutical Co., Ltd.'s (SHSE:688192) Biggest Owners and Were Hit After Market Cap Dropped CN¥2.3b

Key Insights The considerable ownership by public companies in Dizal (Jiangsu) Pharmaceutical indicates that they collectively have a greater say in management and business strategy The top 2 shareh

Simply Wall StJun 30 20:52 ET

Gao Ruizhe's rapid listing in two days landed for the first time, and "Dizhe speed" first benefited Chinese patients.

Shanghai, June 27th, 2024 / PRNewswire / -- Dezera Pharmaceutical (stock code: 688192.SH) has become the first and only company in the world to be approved for its high-selectivity JAK1 inhibitor Gushizeti, which is used to treat lymphoma. Two days after obtaining the Drug Registration Certificate from the National Medical Products Administration (NMPA), Gushizeti has been officially available in hospitals and pharmacies nationwide, and the first prescriptions have been issued across the country. Dr. Zhang Xiaolin, founder, director and CEO of Dezera Pharmaceutical, said: "I am very proud to have achieved the rapid listing of Gushizeti in China within two days, far exceeding the fastest speed of my peers."

PR NewswireJun 27 09:24 ET

Dizal Pharmaceutical Gets Nod to Market Golixitinib Capsules

China's National Medical Products Administration gave its approval for Dizal (Jiangsu) Pharmaceutical (SHA:688192) to market Golixitinib capsules, according to a Thursday filing on the Shanghai Stock

MT NewswiresJun 20 00:50 ET

Golidocitinib Approved in China as First-in-class JAK1 Only Inhibitor for the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma

Golidocitinib is a first-in-class Janus kinase 1 (JAK1) only inhibitor approved for the treatment of r/r PTCL based on results from the multinational pivotal JACKPOT8B study. Golidocitinib monotherap

PR NewswireJun 19 07:30 ET

A global first! DiZhe Pharmaceutical's Gaudrela has been approved for listing in China, breaking the "10-year global no innovative drugs" impasse for peripheral T-cell lymphoma.

Relapsed/refractory peripheral T-cell lymphoma (r/r PTCL) has high malignancy, strong heterogeneity, complex pathogenesis, poor prognosis, and a 3-year survival rate of only 23%. There have been no innovative drugs for r/r PTCL in the past decade, and the efficacy of monotherapy is currently limited, urgently needing breakthroughs in new treatment regimens with significant therapeutic effects. Gerocea is the world's first and only new mechanism treatment drug for PTCL that targets the JAK/STAT pathway. Gerocea monotherapy for PTCL breaks through the treatment bottleneck: achieving deep remission, overall benefit, and longer survival. Shanghai, June 19, 2024 / PRNewswire/

PR NewswireJun 19 05:13 ET

Dizhe Pharmaceutical (688192.SH): Gao Ruizhe (Golixetinib capsules) received approval from the National Medical Products Administration (NMPA) to enter the market.

On June 19th, Gelunhui reported that DiZhe Pharmaceutical (688192.SH) announced that its self-developed Class I new drug Gao Ruizhe (generic name: Gori Xi Ti Ni capsule) has officially been approved by the National Medical Products Administration (NMPA) and is applicable to adult patients with relapsed or refractory peripheral T-cell lymphoma (r/rPTCL) who have received at least first-line systemic treatment. Gao Ruizhe is the world's first and only new drug that acts on the JAK/STAT pathway to treat peripheral T-cell lymphoma. Monotherapy has shown breakthrough advantages in terms of deep symptom relief, comprehensive benefits in all subtypes, and markedly extended survival.

Gelonghui FinanceJun 19 04:41 ET